Literature DB >> 14594546

Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

O C Trifan1, T Hla.   

Abstract

Cyclooxygenase (COX)-2 and the prostaglandins resulting from its enzymatic activity have been shown to play a role in modulating cell growth and development of human neoplasia. Evidence includes a direct relationship between COX-2 expression and cancer incidence in humans and animal models, increased tumorigenesis after genetic manipulation of COX-2, and significant anti-tumor properties of non-steroidal anti-inflammatory drugs in animal models and in some human cancers. Recent data showed that COX-2 and the derived prostaglandins are involved in control of cellular growth, apoptosis, and signal through a group of nuclear receptors named peroxisome proliferator-activated receptors (PPARs). In this article we will review some of the findings suggesting that COX-2 is involved in multiple cellular mechanisms that lead to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594546      PMCID: PMC6741314          DOI: 10.1111/j.1582-4934.2003.tb00222.x

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  138 in total

Review 1.  Role and regulation of cyclooxygenase-2 during inflammation.

Authors:  L S Simon
Journal:  Am J Med       Date:  1999-05-31       Impact factor: 4.965

2.  Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells.

Authors:  T Kinoshita; Y Takahashi; T Sakashita; H Inoue; T Tanabe; T Yoshimoto
Journal:  Biochim Biophys Acta       Date:  1999-04-19

3.  Prostaglandin E1 transported into cells blocks the apoptotic signals induced by nerve growth factor deprivation.

Authors:  T Kawamura; S Horie; T Maruyama; T Akira; T Imagawa; N Nakamura
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

4.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2.

Authors:  D Bishop-Bailey; T Hla
Journal:  J Biol Chem       Date:  1999-06-11       Impact factor: 5.157

6.  Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.

Authors:  X Xin; S Yang; J Kowalski; M E Gerritsen
Journal:  J Biol Chem       Date:  1999-03-26       Impact factor: 5.157

7.  Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells.

Authors:  L R Howe; K Subbaramaiah; W J Chung; A J Dannenberg; A M Brown
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

8.  Interleukin-1 alpha induced cyclooxygenase-2 expression in bone-derived endothelial cells.

Authors:  T Nakagawa; N Fujita; T Oh-Hara; T Kurokawa; K Nakamura; T Tsuruo
Journal:  J Cell Physiol       Date:  1999-05       Impact factor: 6.384

9.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation.

Authors:  S Bunting; R Gryglewski; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1976-12

10.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Authors:  C C Chan; S Boyce; C Brideau; S Charleson; W Cromlish; D Ethier; J Evans; A W Ford-Hutchinson; M J Forrest; J Y Gauthier; R Gordon; M Gresser; J Guay; S Kargman; B Kennedy; Y Leblanc; S Leger; J Mancini; G P O'Neill; M Ouellet; D Patrick; M D Percival; H Perrier; P Prasit; I Rodger
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

View more
  47 in total

1.  Functional polymorphisms of cyclooxygenase-2 gene and risk for hepatocellular carcinoma.

Authors:  Hikmet Akkız; Süleyman Bayram; Aynur Bekar; Ersin Akgöllü; Yakup Ülger
Journal:  Mol Cell Biochem       Date:  2010-11-02       Impact factor: 3.396

2.  Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis.

Authors:  Susan M Fischer; Amy Pavone; Carol Mikulec; Robert Langenbach; Joyce E Rundhaug
Journal:  Mol Carcinog       Date:  2007-05       Impact factor: 4.784

3.  Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032.

Authors:  Eunmiri Roh; Yaping Han; Kanamata Reddy; Tatyana A Zykova; Mee Hyun Lee; Ke Yao; Ruihua Bai; Clara Curiel-Lewandrowski; Zigang Dong
Journal:  Oncogene       Date:  2020-04-10       Impact factor: 9.867

4.  Expression of cyclooxygenase-2 and epidermal growth factor receptor in primary and recurrent glioblastoma multiforme.

Authors:  Peter Sminia; T Rianne Stoter; Paul van der Valk; Paula H M Elkhuizen; Thea M Tadema; Gitta K Kuipers; W Peter Vandertop; M Vincent M Lafleur; Ben J Slotman
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

5.  Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

Authors:  Alfred Haynes; Madhu Sudhan Shaik; Abhijit Chatterjee; M Singh
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

6.  Transcription factor Ets-1 inhibits glucose-stimulated insulin secretion of pancreatic β-cells partly through up-regulation of COX-2 gene expression.

Authors:  Xiong-Fei Zhang; Yi Zhu; Wen-Biao Liang; Jing-Jing Zhang
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 7.  Cyclooxygenases: structural and functional insights.

Authors:  Carol A Rouzer; Lawrence J Marnett
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

8.  The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation.

Authors:  Maria Teresa Valenti; Sandro Giannini; Luca Donatelli; Mirko Zanatta; Francesco Bertoldo; Stefania Sella; Maria Teresa Vilei; Elena Ossi; Giuseppe Realdi; Vincenzo Lo Cascio; Luca Dalle Carbonare
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

9.  The functional -765G→C polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease.

Authors:  Hilbert S de Vries; Rene H M te Morsche; Martijn G H van Oijen; Iris D Nagtegaal; Wilbert H M Peters; Dirk J de Jong
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

10.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.